Blood Res.  2018 Jun;53(2):174-177. 10.5045/br.2018.53.2.174.

Primary CNS lymphoma: latest updates and a 10-year monocenter experience

• Cencini E
• Fabbri A
• Schiattone L
• Cerase A
• Bocchia M

• KMID: 2451041
• DOI: http://doi.org/10.5045/br.2018.53.2.174

Abstract

No abstract available.

MeSH Terms

Lymphoma*

Figure

• 

  Fig. 1 Progression-free survival (PFS) among primary central nervous system lymphoma (PCNSL) patients receiving ≥2 treatment cycles vs. those who underwent early discontinuation.

Reference

1. Qian L, Tomuleasa C, Florian IA, et al. Advances in the treatment of newly diagnosed primary central nervous system lymphomas. Blood Res. 2017; 52:159–166.

2. Eloranta S, Brånvall E, Celsing F, et al. Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000–2013. Eur J Haematol. 2018; 100:61–68.

3. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009; 374:1512–1520.

4. Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3:217–227.

5. Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017; 4:e510–e523.

6. Schorb E, Finke J, Ferreri AJ, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix). BMC Cancer. 2016; 16:282.

7. Grommes C, Pastore A, Palaskas N, et al. Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma. Cancer Discov. 2017; 7:1018–1029.

8. Abramson JS, McGree B, Noyes S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med. 2017; 377:783–784.

9. Mendez JS, Ostrom QT, Gittleman H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018; 20:687–694.

10. Kasenda B, Ferreri AJ, Marturano E, et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol. 2015; 26:1305–1313.

11. Fritsch K, Kasenda B, Schorb E, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017; 31:846–852.

12. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23:5034–5043.

13. Wang H, Wang M, Wei J, Wang L, Mao L, Jin J. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre. J Int Med Res. 2018; 46:883–894.

14. Burton EC, Ugiliweneza B, Kolikonda MK, et al. A regional multicenter retrospective analysis of patients with primary central nervous system lymphoma diagnosed from 2000–2012: treatment patterns and clinical outcomes. Cureus. 2017; 9:e1512.